Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting of liposomes to angiogenic endothelial cells.
Schiffelers RM, Molema G, Ten Hagen TL, Janssen AP, Schraa AJ, Kok RJ, Koning GA, Storm G. Schiffelers RM, et al. Among authors: kok rj. Cell Mol Biol Lett. 2002;7(2):255. Cell Mol Biol Lett. 2002. PMID: 12097939 No abstract available.
Ligand-targeted liposomes directed against pathological vasculature.
Schiffelers RM, Molema G, ten Hagen TL, Janssen AP, Schraa AJ, Kok RJ, Koning GA, Storm G. Schiffelers RM, et al. Among authors: kok rj. J Liposome Res. 2002 Feb-May;12(1-2):129-35. doi: 10.1081/lpr-120004785. J Liposome Res. 2002. PMID: 12604046
Peptide-targeted PEG-liposomes in anti-angiogenic therapy.
Janssen AP, Schiffelers RM, ten Hagen TL, Koning GA, Schraa AJ, Kok RJ, Storm G, Molema G. Janssen AP, et al. Among authors: kok rj. Int J Pharm. 2003 Mar 18;254(1):55-8. doi: 10.1016/s0378-5173(02)00682-8. Int J Pharm. 2003. PMID: 12615409
Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin.
Schiffelers RM, Koning GA, ten Hagen TL, Fens MH, Schraa AJ, Janssen AP, Kok RJ, Molema G, Storm G. Schiffelers RM, et al. Among authors: kok rj. J Control Release. 2003 Aug 28;91(1-2):115-22. doi: 10.1016/s0168-3659(03)00240-2. J Control Release. 2003. PMID: 12932643
Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis.
Prakash J, Sandovici M, Saluja V, Lacombe M, Schaapveld RQ, de Borst MH, van Goor H, Henning RH, Proost JH, Moolenaar F, Këri G, Meijer DK, Poelstra K, Kok RJ. Prakash J, et al. Among authors: kok rj. J Pharmacol Exp Ther. 2006 Oct;319(1):8-19. doi: 10.1124/jpet.106.106054. Epub 2006 Jun 28. J Pharmacol Exp Ther. 2006. PMID: 16807361
Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology.
Temming K, Lacombe M, van der Hoeven P, Prakash J, Gonzalo T, Dijkers EC, Orfi L, Kéri G, Poelstra K, Molema G, Kok RJ. Temming K, et al. Among authors: kok rj. Bioconjug Chem. 2006 Sep-Oct;17(5):1246-55. doi: 10.1021/bc0600158. Bioconjug Chem. 2006. PMID: 16984135
Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells.
Gonzalo T, Beljaars L, van de Bovenkamp M, Temming K, van Loenen AM, Reker-Smit C, Meijer DK, Lacombe M, Opdam F, Kéri G, Orfi L, Poelstra K, Kok RJ. Gonzalo T, et al. Among authors: kok rj. J Pharmacol Exp Ther. 2007 Jun;321(3):856-65. doi: 10.1124/jpet.106.114496. Epub 2007 Mar 16. J Pharmacol Exp Ther. 2007. PMID: 17369283
142 results